Luis Peña, Evommune CEO

Af­ter get­ting their can­di­dates back from Eli Lil­ly, the old Der­mi­ra team is dash­ing for the clin­ic

Af­ter get­ting bought out by Eli Lil­ly for $1 bil­lion last year, the old Der­mi­ra team re­grouped in Jan­u­ary with their own up­start and three in­flam­ma­to­ry dis­ease pro­grams li­censed back from the Big Phar­ma. Now, the small team has $83 mil­lion more to work with.

Evom­mune un­veiled an $83 mil­lion Se­ries A round on Thurs­day morn­ing, which will be used to push its first three can­di­dates in­to the clin­ic. First up is IRAK4/Tr­kA, a small mol­e­cule that broad­ly in­hibits in­nate in­flam­ma­tion, which CEO Luis Peña says should en­ter the clin­ic this year. The team is look­ing to tack­le atopic der­mati­tis and rosacea, with the first clin­i­cal read­out ex­pect­ed next year.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.